Provided by Tiger Fintech (Singapore) Pte. Ltd.

Lexicon Pharmaceuticals

0.7451
-0.0216-2.82%
Post-market: 0.74990.0048+0.64%17:56 EDT
Volume:3.89M
Turnover:2.92M
Market Cap:270.60M
PE:-1.47
High:0.7943
Open:0.7700
Low:0.7130
Close:0.7667
Loading ...

Leerink Partners Downgrades Lexicon Pharmaceuticals to Market Perform From Outperform, Adjusts PT to $1 From $2

MT Newswires Live
·
05 Mar

Lexicon Pharma Cut to Market Perform From Outperform by Leerink Partners

Dow Jones
·
05 Mar

Lexicon downgraded to Market Perform from Outperform at Leerink

TIPRANKS
·
05 Mar

Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

GlobeNewswire
·
05 Mar

Lexicon Pharma Price Target Maintained With a $4.00/Share by HC Wainwright & Co.

Dow Jones
·
04 Mar

H.C. Wainwright Remains a Buy on Lexicon Pharmaceuticals (LXRX)

TIPRANKS
·
04 Mar

Lexicon Pharmaceuticals’ Promising Phase 2b Trial Results for Pilavapadin Drive Buy Rating

TIPRANKS
·
04 Mar

Lexicon Pharmaceuticals (LXRX) Gets a Hold from Needham

TIPRANKS
·
04 Mar

Lexicon Says Pilavapadin Showed 'Meaningful' Pain Reduction But Results Miss Primary Endpoint

MT Newswires Live
·
03 Mar

Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain

GlobeNewswire
·
03 Mar

Lexicon’s sotagliflozin shows cardiovascular efficacy in published study

TIPRANKS
·
18 Feb

ANALYSIS-Europe's AI bulls pin hopes on 'Jevons Paradox' after DeepSeek rout

Reuters
·
04 Feb

Promising Outlook for Lexicon Pharmaceuticals’ LX9211 as a Novel Treatment for Diabetic Peripheral Neuropathic Pain

TIPRANKS
·
30 Jan

Lexicon rumor highlighted in Betaville alert

TIPRANKS
·
30 Jan

Lexicon Pharma Price Target Maintained With a $4.00/Share by HC Wainwright & Co.

Dow Jones
·
29 Jan

Lexicon Pharmaceuticals (LXRX) Gets a Hold from Needham

TIPRANKS
·
29 Jan

Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX) and Allakos (ALLK)

TIPRANKS
·
28 Jan

Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain

GlobeNewswire
·
21 Jan

Here’s Why Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Is Among the Best Diabetes Stocks to Buy Under $10

Insider Monkey
·
06 Jan

Lexicon Pharmaceuticals Names Scott Coiante Finance Chief

Dow Jones
·
02 Jan